Purple Biotech Ltd.
NASDAQ Capital MarketTotal Valuation
Purple Biotech Ltd. carries a market capitalization of 196,079.00, placing it among publicly traded companies globally. Its enterprise value stands at -3.42M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 196,079.00 |
| Enterprise Value | -3.42M |
Share Statistics
Purple Biotech Ltd. currently has 1.86B shares outstanding.
| Shares Outstanding | 1.86B |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | -0.02 |
| P/TBV Ratio | 1.25 |
| P/FCF Ratio | -0.42 |
| P/OCF Ratio | -0.42 |
Financial Position
Purple Biotech Ltd. maintains a current ratio of 1.48, meaning it holds 1.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 1.90, indicating elevated leverage, while an interest coverage ratio of -128.71 demonstrates limited ability to service its debt obligations.
| Current Ratio | 1.48 |
| Quick Ratio | 1.40 |
| Debt / Equity | 1.90 |
| Debt / EBITDA | -0.02 |
| Interest Coverage | -128.71 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -104.05 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Purple Biotech Ltd.'s stock has declined approximately -94.79853% over the past 52 weeks. The 50-day moving average sits at 2.37, while the 200-day moving average is 5.09.
| Beta (5Y) | N/A |
| 52-Week Price Change | -94.79853% |
| 50-Day Moving Average | 2.37 |
| 200-Day Moving Average | 5.09 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -7.59M, while operating income came in at -7.82M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -7.82M |
| Pretax Income | -26.12M |
| Net Income | -26.02M |
| EBITDA | -7.59M |
| EBIT | -7.82M |
| Earnings Per Share (EPS) | -36.64 |
Balance Sheet
Purple Biotech Ltd. holds 6.43M in cash and equivalents against 184,000.00 in total debt, resulting in a net debt position of -5.57M. Total book value stands at -171.17M, with working capital of 2.19M providing operational flexibility.
| Cash & Cash Equivalents | 6.43M |
| Total Debt | 184,000.00 |
| Net Debt | -5.57M |
| Equity (Book Value) | -171.17M |
| Book Value Per Share | -240.04 |
| Working Capital | 2.19M |
Cash Flow
Purple Biotech Ltd. produced -6.80M in operating cash flow over the past twelve months.
| Operating Cash Flow | -6.80M |
| Capital Expenditures | N/A |
| Free Cash Flow | -6.80M |
| FCF Per Share | -9.53 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -214.04 |
| FCF Yield | -236.01 |
Stock Splits
Purple Biotech Ltd.'s most recent stock split took place on March 2, 2026 with a 10:1 split ratio.
| Last Split Date | 3/2/2026 |
| Split Ratio | 10:1 |
Scores
Purple Biotech Ltd. posts an Altman Z-Score of -36.88, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -36.88 |